PRODUCTION OF AN ACELLULAR PERTUSSIS VACCINE (TOXOID)

无细胞百日咳疫苗（类毒素）的生产

• 批准号: 2316497
• 负责人: SHARON MATES
• 金额: $ 30.45万
• 依托单位: AMVAX
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-04-06 至 1992-01-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2316497
• 关键词: PRODUCTION; ACELLULAR; PERTUSSIS; VACCINE; TOXOID

The NICHD is continuing its evaluation of the NICHD acellular pertussis toxoid through combination of the pertussis toxoid with diphtheria and tetanus toxoids, resulting in a trivalent, DTP, vaccine. The referenced contract is being modified to include the development of this trivalent product for efficacy testing in clinical trials in Sweden and the U.S. AMVAX has submitted a proposal for the continued production of the pertussis toxoid, and its combination with purchased diphtheria and tetanus toxoids. Representatives of the NICHD (including the Director, NICHD) have reviewed the progress that the contractor has made in the development of a bulk pertussis toxoid. It has been determined that AMVAX shall supply the NICHD with 0.7 grams of the combined bulk DTP vaccine by November 1, 1990, and an additional 1.0 gram of the bulk DTP vaccine to be delivered by January 31, 1991.

NICHD正在继续对NICHD非细胞百日咳进行评估